美国食品药品监督管理局（FDA）已向 Applied Therapeutics 公司发出了一份完整回复函（CRL），涉及 govorestat 用于治疗经典半乳糖血症的新药申请（NDA）。 该 NDA 包含 1/2 期 ...

If you suffered losses exceeding $50,000 in Applied Therapeutics January 3, 2024 and December 2, 2024 and would like to ...

central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.” According to the Company, “[t]he CRL indicates that the FDA completed its review of ...

This is an up-to-date listing of the entire PlayStation Plus Classics Catalog. You can browse, sort, and tag the titles and use them to build your own playlists. Sort by "Recently Added" to see ...

The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic ...